Ovarian Cancer Awareness Month: what the symptoms are and why early detection is so difficult

The teal ribbon associated with ovarian cancer first appeared in the mid-1990s, introduced by advocacy organizations working to give a hard-to-detect disease a visible public identity. A dedicated awareness week followed at the end of that decade, and by the early 2000s the observance now known as Ovarian Cancer Awareness Month covered the full month of September in the United States. That expansion reflected a practical problem rather than a symbolic one, because ovarian cancer remains difficult to identify early and public familiarity with its warning signs continues to lag behind familiarity with other cancers.

What ovarian cancer is and where it begins

The ovaries are two small organs, roughly the size and shape of almonds, positioned on either side of the uterus. They release eggs and produce the hormones estrogen and progesterone. Ovarian cancer describes a group of related but distinct diseases rather than a single condition, grouped by the type of cell where abnormal growth starts.

The large majority of cases are epithelial ovarian cancer, meaning the cancer begins in the thin layer of cells covering the outer surface of the ovary or lining the fallopian tube. Within that group, the most common and most aggressive form is high-grade serous carcinoma. The word serous refers to a cell type resembling the lining of the fallopian tube, and high-grade means the cells appear markedly abnormal under a microscope and tend to grow quickly.

Two rarer categories also exist: germ cell tumors, which begin in the cells that produce eggs and occur most often in younger people, and stromal tumors, which begin in the hormone-producing tissue of the ovary.

Scientific understanding of where these cancers start has shifted considerably over the past two decades. Evidence now indicates that a substantial share of high-grade serous cancers originate in small precancerous changes within the fallopian tube rather than in the ovary itself. That shift is a clear illustration of how research changes medical understanding, and it has redirected both prevention and early detection efforts toward the fallopian tubes.

Ovarian cancer symptoms and what makes them easy to miss

Ovarian cancer is often described as producing no symptoms at all. That description is inaccurate. Symptoms are usually present, but they are vague and closely resemble the symptoms of far more common and far less serious conditions.

The symptoms most consistently associated with ovarian cancer include the following:

• Bloating, or a visible increase in abdominal size
• Pelvic or abdominal pain and pressure
• Feeling full quickly during meals, or difficulty eating
• Urinary urgency or increased frequency
• Changes in bowel habits, including constipation
• Persistent fatigue
• Back pain
• Unexplained weight loss or weight gain
• Menstrual changes, or any vaginal bleeding after menopause

Bloating, indigestion, and fatigue are ordinary experiences for most adults, which is precisely why this cluster is so easily set aside. What distinguishes a pattern worth investigating is change, persistence, and frequency. Federal health agencies advise consulting a clinician when such symptoms are new, occur on most days, and continue for roughly two weeks or longer without a clear explanation.

Vaginal bleeding after menopause deserves separate emphasis. Bleeding that occurs once menstrual periods have permanently stopped is never considered normal and warrants prompt evaluation, however minor it appears.

Researchers have formalized this pattern into a symptom index, a scoring approach weighing how often symptoms occur and how long they have been present. Tools of this kind improve awareness, yet they were never designed as diagnostic tests and they miss a meaningful number of early cancers. Public education work led by patient advocacy organizations has concentrated heavily on this symptom cluster for that reason.

Why there is no routine ovarian cancer screening test

Screening means testing people who feel well in order to find disease before symptoms appear. Mammography for breast cancer and colonoscopy for colorectal cancer are familiar examples. An equivalent test does not exist for ovarian cancer in women at average risk.

Two tests are frequently assumed to serve this purpose. The first is a blood test measuring CA-125, a protein that can rise when ovarian cancer is present. The second is transvaginal ultrasound, an imaging test producing pictures of the ovaries from inside the vagina. Both were evaluated in very large randomized studies, and neither reduced deaths from ovarian cancer.

Two problems explain that outcome. CA-125 rises in many harmless situations, including endometriosis, uterine fibroids, pelvic infection, and ordinary menstruation, and it fails to rise in many early cancers. Ultrasound frequently identifies cysts and masses that prove to be benign. The combined effect is a large volume of false alarms, some leading to surgery that was never necessary, without a corresponding gain in lives saved.

The national body that reviews preventive services in the United States therefore recommends against screening women who have no symptoms and no elevated risk. That recommendation does not extend to women with a known inherited mutation or a strong family history, whose care is planned individually with a specialist. CA-125 retains an important role after a diagnosis, where it is used to follow how a cancer is responding and to watch for recurrence.

Early detection remains an open research question rather than a settled one. Investigators are studying blood tests capable of detecting fragments of tumor DNA in circulation, alongside approaches that focus directly on the fallopian tubes. Studies of this kind sit outside conventional therapy research, and understanding prevention and treatment studies as separate categories makes that distinction clearer.

Risk factors, genetic testing, and steps that lower risk

Risk for ovarian cancer rises with age and is highest after menopause. A family history of ovarian, breast, or related cancers raises risk, as do inherited mutations in the BRCA1 and BRCA2 genes and in the mismatch repair genes associated with Lynch syndrome. Endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus, is linked to certain subtypes.

Several factors are associated with lower risk, including pregnancy, breastfeeding, use of oral contraceptives, and surgical procedures involving the fallopian tubes. The protective association with oral contraceptives appears to persist for many years after use has stopped.

Professional guidelines now recommend that anyone diagnosed with epithelial ovarian cancer be offered genetic testing. Two kinds of testing are involved. Germline testing examines genes a person was born with, using a blood or saliva sample, and a result can carry implications for close relatives. Somatic testing examines the tumor tissue for changes that arose within the cancer and were not inherited.

Genetic counseling is the conversation that surrounds this testing. A genetic counselor or specially trained clinician explains what a result means, what it does not mean, and which options follow from it. Results also influence which studies a person may qualify to join, which is one reason why eligibility rules exist in research protocols at all.

Prevention research has moved in a specific direction because of the fallopian tube findings. Removing the fallopian tubes during a pelvic surgery already planned for another reason is now supported by gynecologic professional bodies for women who have completed childbearing.

How ovarian cancer research is expanding and where participation fits

Care for ovarian cancer follows a recognizable sequence. Surgery aims to remove as much visible disease as possible, a procedure referred to as cytoreduction or debulking. Chemotherapy combining a platinum-based drug class with a taxane drug class follows the surgery, or in some cases precedes it in order to reduce the amount of disease first. Maintenance therapy may then be used to delay return of the cancer, drawing on the PARP inhibitor drug class and on drug classes that interfere with tumor blood vessel growth.

Biomarkers increasingly guide those decisions. Tumors carrying BRCA mutations, or showing homologous recombination deficiency, meaning the cancer cannot repair its own DNA properly, respond particularly well to certain targeted approaches.

Research activity in ovarian cancer is substantial. Active studies include those testing new study interventions, comparing maintenance strategies, evaluating antibody drug conjugates that deliver a cell-killing payload directly to proteins found on cancer cells, testing immunotherapy combinations, and developing earlier detection methods. Government-maintained public trial registries list studies currently open to enrollment.

Locating a suitable study is harder than the volume of research suggests, and the reasons are structural. Studies concentrate at academic medical centers, which creates travel burden for people receiving care in community settings. Eligibility criteria involve prior lines of therapy, specific biomarkers, measures of daily functioning, and required gaps between therapies. Diagnosis at an advanced stage compresses the window for decisions, and referral pathways between community practices and research centers carry friction. Underrepresentation in ovarian cancer research reflects unequal access to these pathways rather than unwillingness to take part.

DecenTrialz operates within that gap. A person who shares information about their diagnosis and health history can be matched against studies that appear relevant, after which a registered nurse conducts a pre-screening conversation to review the basic details more carefully. Final eligibility determination, informed consent, the full study walk-through, and enrollment are always handled by the research site team. Anyone weighing participation can review the steps involved in finding a study before making contact.

Frequently asked questions about ovarian cancer

What are the earliest symptoms of ovarian cancer?

Bloating, pelvic or abdominal pain, feeling full quickly, and urinary urgency are reported most consistently. Each can occur for entirely benign reasons, so the pattern that matters is a symptom that is new, occurs on most days, and continues for roughly two weeks or longer.

Is there a screening test for ovarian cancer?

No routine screening test is recommended for women at average risk. Large randomized studies of CA-125 blood testing and transvaginal ultrasound did not reduce deaths and produced many false alarms. Women with inherited high risk or a strong family history should discuss individualized monitoring with a specialist.

Who should consider genetic testing?

Professional guidelines recommend offering genetic testing to everyone diagnosed with epithelial ovarian cancer. People with a family history of ovarian, breast, or related cancers may also benefit from a genetic counseling conversation, where the value and limits of testing are explained before any sample is taken.

Do participants in cancer studies receive a placebo instead of care?

This concern reflects a misunderstanding of how cancer studies are designed. Participants are not knowingly denied effective care. A placebo is generally used only where no established option exists, or is added on top of standard care so that one group receives standard care plus the study intervention and the other receives standard care plus a placebo.

What does pre-screening involve?

Pre-screening is a preliminary review of basic information such as diagnosis, cancer subtype, prior therapies, and biomarker results, carried out to see whether a person might fit a given study. A pre-screening conversation is not an eligibility decision and does not commit anyone to taking part.

What Ovarian Cancer Awareness Month can realistically change

Ovarian cancer sits in an uncomfortable position among cancers, common enough to affect a great many families yet lacking the reliable screening test that has reshaped outcomes elsewhere. Until such a test exists, the practical levers are narrower and more ordinary: recognizing a symptom pattern that persists, raising it with a clinician rather than waiting for it to resolve, taking family history seriously, and knowing that genetic testing is now standard practice after a diagnosis. Ovarian Cancer Awareness Month succeeds to the degree that it moves those specific behaviors rather than simply raising the profile of the disease.

Research participation is a further avenue, and it depends on people knowing that studies exist and that a suitable one may be within reach. Anyone interested in exploring ovarian cancer studies can share their information with DecenTrialz to be matched against relevant research and to speak with a registered nurse during pre-screening. Final eligibility decisions and enrollment steps are handled by the research site team. Nothing in this article is medical advice, and decisions about symptoms, testing, or care belong with a qualified clinician.